Why Did Unity Biotechnology Plunge 8.85%? Nasdaq Delisting Looms

On July 1, 2025, Unity Biotechnology's stock experienced a significant drop of 8.85% in pre-market trading, marking a tumultuous period for the biotech company.

Unity Biotechnology has been facing a series of challenges that have led to its recent stock decline. The company received a notice from Nasdaq's Listing Qualifications Department on June 27, indicating that its stock would be delisted due to diminished operations and failure to meet continued listing standards. The notice cited recent layoffs, the shutdown of its ASPIRE study, and limited investment in revenue-generating projects as reasons for the delisting.

Unity Biotechnology has acknowledged the notice and does not intend to appeal the delisting. Trading is expected to be suspended on July 9, after which Nasdaq will file to officially deregister the securities with the U.S. Securities and Exchange Commission. This delisting comes after a string of compliance failures, including falling below the $10 million stockholders' equity requirement in March and the stock remaining under $1 for 30 consecutive trading days in June.

The company's board approved an operating plan in May to cut costs and explore options for its future. However, the delisting marks a major setback for Unity Biotechnology, which had been developing anti-aging and cellular senescence therapies. The company currently has no meaningful revenue and is evaluating strategic alternatives.